On the heels of a $15 million Series C financing, Adnexus Therapeutics Inc. filed for an initial public offering, hoping to raise as much as $86 million to fund ongoing work with its anti-angiogenic drug, Angiocept, and other early stage Adnectin-based products. (BioWorld Today)

Shares in Pharming Group NV rose more than 27 percent Monday on news that it stopped a placebo-controlled clinical trial of Rhucin in hereditary angioedema (HAE) on ethical grounds, following advice from an independent data monitoring committee. An interim analysis of the data indicated that none of the patients treated during the study experienced a relapse, and no adverse events were reported. (BioWorld International)